SCHEMBL6318960

SCHEMBL6318960

Cc1ccsc1-c1noc(N)c1C(=O)NCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.45
EPHX2 P34913 4/20 0.44
NR1H4 Q96RI1 1/20 0.44
SCN3A Q9NY46 1/20 0.43
PDE2A O00408 1/20 0.43
PPARA Q07869 3/20 0.42
PPARD Q03181 1/20 0.42
HTR2C P28335 1/20 0.42
PPARG P37231 2/20 0.41
FLT1 P17948 1/20 0.40
KDR P35968 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.39
PTGS2 P35354 1/20 0.38
KLKB1 P03952 1/20 0.38
MAPK8 P45983 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322727 0.89 ALDH1A1 (0.50) FLT1POLBALDH1A1SMN1; SMN2MAPT
SCHEMBL6318520 0.88 SMN1; SMN2 (0.42) EPHX2SCN3APPARAPPARGFLT1
SCHEMBL6315404 0.86 KMT2A (0.47) POLBALDH1A1SMN1; SMN2MAPT
SCHEMBL6318418 0.84 POLB (0.53) POLBALDH1A1SMN1; SMN2MAPT
SCHEMBL6315045 0.83 ADRB2 (0.47) ADRB2EPHX2NR1H4PDE2APPARA
SCHEMBL6316645 0.83 TACR1 (0.44) POLB
SCHEMBL6318410 0.82 POLB (0.42) PPARGPOLBALDH1A1
SCHEMBL6321626 0.81 ADRB2 (0.47) ADRB2EPHX2NR1H4PDE2APPARA
SCHEMBL6322463 0.81 NPC1 (0.46) POLB
SCHEMBL6324517 0.80 NAMPT (0.47) POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ADRB2 3527/4885EPHX2 4156/4885NR1H4 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.